

part I: invited papers

target therapies

monoclonal antibodies anti-EGFR and anti-VEGF

From the trastuzumab era to new target therapies:
beyond revolution

S. Barni, F. Petrelli, M. Cabiddu, M. E. Cazzaniga &
M. Cremonesi

vi1

Cetuximab in squamous cell head and neck carcinomas
V. Gebbia, F. Giuliani, V. M. Valori, R. Agueli,
G. Colucci & E. Maiello

vi5

Cetuximab: clinical results in colorectal cancer
E. Maiello, F. Giuliani, V. Gebbia, A. Piano,
R. Agueli & G. Colucci

vi8

Safety and activity of trastuzumab-containing therapies
for the treatment of metastatic breast cancer:

Our long-term clinical experience (GOIM Study)
V. Adamo, T. Franchina, B. Adamo, G. Ferraro,
R. Rossello, M. Maugeri Saccà, C. Scibilia,
M. R. Valerio & A. Russo

vi11

Panitumumab a novel drug in cancer treatment
G. Carteni, R. Fiorentino, L. Vecchione,
B. Chiurazzi & C. Battista

vi16

small molecule kinasi inhibitors

Protein kinase inhibitors in the treatment of renal
cell carcinoma: sorafenib

S. Bracarda, C. Caserta, L. Sordini, M. Rossi,
A. Hamzay & L. Crinò

vi22

Lapatinib in breast cancer

D. Bilancia, G. Rosati, A. Dinota, D. Germano,
R. Romano & L. Manzione

vi26

Sunitinib: bridging present and future
cancer treatment

A. M. Grimaldi, T. Guida, R. D'Attino, E. Perrotta,
M. Otero, A. Masala & G. Carteni

vi31

Erlotinib in cancer treatment

M. A. Bareschino, C. Schettino, T. Troiani, E. Martinelli,
F. Morgillo & F. Ciardiello

vi35

Dasatinib: a new step in molecular target therapy

A. Olivieri & L. Manzione

vi42

The role of Aurora-A inhibitors in cancer therapy

V. Agnese, V. Bazan, F. P. Fiorentino, D. Fanale,
G. Badalamenti, G. Colucci, V. Adamo, D. Santini & A. Russo

vi47

breast and ovarian cancer

Overview and new strategies in metastatic breast cancer
(MBC) for treatment of tamoxifen-resistant patients
V. Adamo, M. Iorfida, E. Montalto, V. Festa, C. Garipoli,
A. Scimone, M. Zanghi & N. Caristi

vi53

Clinical and therapeutic perspectives of gene
expression profiling for breast cancer
V. E. Chiuri, G. Leo & V. Lorusso

vi58

Adjuvant strategies in breast cancer: new perspectives,
questions and reflections at the end of 2007 St Gallen
International Expert Consensus Conference
S. Cinieri, L. Orlando, P. Fedele, A. Cusmai, M. D'Amico,
P. Rizzo & M. C. Chetri

vi63

Liposomal-encapsulated doxorubicin plus
cyclophosphamide as first-line therapy in metastatic
breast cancer: a phase II multicentric study
F. Giotta, V. Lorusso, E. Maiello, G. Filippelli, M. R. Valerio,
M. Caruso, F. Verderame, A. Latorre & G. Colucci

vi66

Role of liposomal anthracyclines in breast cancer
V. Lorusso, L. Manzione & N. Silvestris

vi70

Management of advanced breast cancer
L. Orlando, M. Colleoni, P. Fedele, A. Cusmai, P. Rizzo,
M. D'Amico, M. C. Chetri & S. Cinieri

vi74

Emotional expression and coping style in female
breast cancer
G. Manna, E. Foddai, M. G. Di Maggio, F. Pace,
G. Colucci, N. Gebbia & A. Russo

vi77

The estrogen receptor α :insulin receptor substrate
1 complex in breast cancer: structure-function relationships
D. Sisci, C. Morelli, S. Cascio, M. Lanzino, C. Garofalo,
K. Reiss, M. Garcia, A. Russo, S. Andò & E. Surmacz

vi81

High prevalence of *BRCA1* deletions in *BRCAPRO*-positive
patients with high carrier probability
S. Veschi, G. Aceto, A. P. Scioletti, V. Gatta, G. Palka,
A. Cama, R. Mariani-Costantini, P. Battista, V. Calò,
F. Barbera, V. Bazan, A. Russo & L. Stuppia

vi86

Founder mutations in *BRCA1* and *BRCA2* genes
R. Ferla, V. Calò, S. Cascio, G. Rinaldi, G. Badalamenti,
I. Carreca, E. Surmacz, G. Colucci, V. Bazan & A. Russo

vi93

4843delC of the *BRCA1* gene is a possible founder
mutation in Southern Italy (Sicily)

A. Russo, V. Calò, C. Augello, L. Bruno, V. Agnese, V. Schirò,
F. Barbera, S. Cascio, E. Foddai, G. Badalamenti, C. Intrivici,
M. Cajozzo, G. Gulotta, E. Surmacz, G. Colucci, N. Gebbia &
V. Bazan

vi99

Continued overleaf

gastro-intestinal cancer

Aberrant methylation within *RUNX3* CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study
G. Gargano, D. Calcara, S. Corsale, V. Agnese, C. Intrivici, F. Fulfaro, G. Pantuso, M. Cajozzo, V. Morello, R. M. Tomasino, L. Ottini, G. Colucci, V. Bazan & A. Russo vii03

Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus
V. Agnese, D. Cabibi, D. Calcara, M. Terrasi, G. Pantuso, E. Fiorentino, C. Intrivici, G. Colucci, F. Aragona, N. Gebbia, V. Bazan & A. Russo vii10

Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 α in human colorectal cancer
M. Koda, M. Sulkowska, L. Kanczuga-Koda, S. Cascio, G. Colucci, A. Russo, E. Surmacz & S. Sulkowski vii16

Neo-adjuvant and adjuvant chemotherapy of gastric cancer
F. De Vita, F. Giuliani, G. Galizia, C. Belli, G. Aurilio, G. Santabarbara, F. Ciardiello, G. Catalano & M. Orditura vii20

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
V. Gebbia, E. Maiello, F. Giuliani, N. Borsellino, M. Caruso, G. Di Maggio, F. Ferrai, R. Bordonaro, F. Verderame, P. Tralongo, L. Di Cristina, R. Agueli, P. Russo & G. Colucci vii24

Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study
G. Rosati, D. Bilancia, D. Germano, A. Dinota, R. Romano, G. Reggiardo & L. Manzione vii28

Chemoradiotherapy as adjuvant treatment of gastric cancer
M. Orditura, E. Martinelli, G. Galizia, F. Vitiello, M. Fasano, P. Muto, F. Ciardiello & F. De Vita vii33

Gastrointestinal stromal tumours (GISTs): focus on histopathological diagnosis and biomolecular features
G. Badalamenti, V. Rodolico, F. Fulfaro, S. Cascio, C. Cipolla, G. Cicero, L. Incorvaia, M. Sanfilippo, C. Intrivici, L. Sandonato, G. Pantuso, M. A. Latteri, N. Gebbia & A. Russo vii36

cancer of the urinary system

Integrated therapy of kidney cancer
R. Longo, M. R. D'Andrea, R. Sarmiento, F. Salerno & G. Gasparini vii41

Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
M. Guida & G. Colucci vii49

Therapy of metastatic bladder carcinoma
R. V. Iaffaioli, A. Milano & F. Caponigro vii53

Role of external radiation therapy in urinary cancers
S. Parisi, M. Troiano, P. Corsa, A. Raguso, S. Cossa, E. E. Piazzolla, T. Mumafò, G. Sanpaolo, A. Natuno & E. Maiello vii57

Neo-adjuvant and adjuvant chemotherapy in bladder cancer
G. D'Auria, M. Ciprotti, D. Conte, R. Iacovelli, A. Palazzo, A. Pellegrino & E. Cortesi vii62

miscellaneous cancer

New developments of aminobisphosphonates: the double face of Janus
D. Santini, S. Galluzzo, B. Vincenzi, G. Schiavon, E. Fratto, F. Pantano & G. Tonini vii64

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis
G. Campisi, O. Di. Fede, A. Musciotto, A. Lo. Casto, L. Lo. Muzio, F. Fulfaro, G. Badalamenti, A. Russo & N. Gebbia vii68

Analysis of extended genomic rearrangements in oncological research
L. De Lellis, M. C. Curia, G. M. Aceto, S. Toracchio, G. Colucci, A. Russo, R. Mariani-Costantini & A. Cama vii73

Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM)
S. Barni, M. Venturini, G. D. Beretta, S. Gori, A. Molino, C. Carnaghi, R. Labianca, S. Sgarbi, L. Simoni & E. Maiello vii79

On behalf of the AIOM Guidelines Task Force

part II: abstracts

Breast cancer vii85

Ovarian and prostate cancer vii87

Gastrointestinal cancer vii88

Head and neck cancer vii91

Melanoma vii92

Miscellaneous cancer vii93

Author index vii97